Phase 2 Oesophageal Cancer Trial, Recruiting NCT05507411 Sponsor: Zhejiang Cancer Hospital Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT05507411
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form and follow the trial schedule, including visits, treatments, and lab tests
  • Your physical fitness level is rated 0 or 1 on a standard activity scale (meaning you are fully active or have only minor limitations in strenuous activity)
  • You have been diagnosed with esophageal cancer in the chest area, confirmed by a tissue sample, and your cancer is at a specific stage that has not spread to distant parts of the body (confirm with trial site for exact staging)
  • You have at least one measurable area of cancer that can be tracked during the trial
  • A tissue sample from your tumor is available for a specific protein test (called PD-L1 testing)
  • Your doctors have determined that your overall health can safely support esophageal surgery
  • You are between 18 and 75 years old
  • If you are a woman who could become pregnant, you must have a negative pregnancy test within 24 hours before starting treatment
  • You must not be breastfeeding if you are a woman

Who may not be able to join:

  • Your cancer has spread to other parts of the body or cannot be surgically removed
  • You have moderate or severe nerve damage in your hands or feet (Grade 2 or higher peripheral neuropathy)
  • You have an active autoimmune disease (a condition where your immune system attacks your own body) — some milder conditions like type 1 diabetes, underactive thyroid managed with hormones only, or certain skin conditions may still be allowed (confirm with trial site)
  • You are currently taking high-dose steroid medicines or other drugs that suppress your immune system (with some exceptions — confirm with trial site)
  • You have HIV or AIDS
  • You have received previous chest radiation, chemotherapy, immunotherapy, or surgery involving your esophagus or stomach before joining the trial
  • You have serious heart or lung disease, or a history of a lung condition called interstitial pneumonia
  • You have significant esophageal ulcers, severe chest or back pain, or signs of a hole in your esophagus
  • Your blood test results fall outside of safe ranges, including low white blood cells, low platelets, low red blood cells, or poor kidney or liver function (confirm with trial site for specific numbers)
  • You have active hepatitis B or hepatitis C infections (some people with past infections may still qualify — confirm with trial site)
  • You have had another cancer within the past 3 years, with some exceptions for certain easily treated skin or surface cancers
  • You have a known allergy or sensitivity to any of the medicines used in this trial
  • You have an active infection requiring treatment within 14 days before starting the trial
  • You are unable or unwilling to understand and follow the trial requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Qixun Chen, Zhejiang Cancer Hospital

Phone: +86-13958108371

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Zhejiang Cancer Hospital
Registry
ClinicalTrials.gov
Start date
3 August 2022
Est. completion
1 April 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

1-year DFS of CCR-Watch and Wait group

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov